drugset / Trial / NCT00314925

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

NCT00314925 ↗

Phase 1 Unknown 60 enrolled Neotropix
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.

Timeline

Start
2006-04
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Seneca Valley Virus Other / unclassified 1e+07 unknown Intravenous

Indications